Show simple item record

dc.contributor.authorDoddakula, Kishore K
dc.contributor.authorNeary, Peter M
dc.contributor.authorWang, Jiang H
dc.contributor.authorSookhai, Shastri
dc.contributor.authorO'Donnell, Aongus
dc.contributor.authorAherne, Tom
dc.contributor.authorBouchier-Hayes, David J
dc.contributor.authorRedmond, Henry P
dc.date.accessioned2012-01-05T12:24:13Z
dc.date.available2012-01-05T12:24:13Z
dc.date.issued2010-09
dc.identifier.citationThe antiendotoxin agent taurolidine potentially reduces ischemia/reperfusion injury through its metabolite taurine. 2010, 148 (3):567-72 Surgeryen
dc.identifier.issn1532-7361
dc.identifier.pmid20223497
dc.identifier.doi10.1016/j.surg.2010.01.006
dc.identifier.urihttp://hdl.handle.net/10147/200243
dc.description.abstractCardiopulmonary bypass results in ischemia/reperfusion (I/R)-induced endotoxemia. We conducted a prospective randomized trial to investigate the effect of taurolidine, an antiendotoxin agent with antioxidant and membrane-stabilizing properties, on patients undergoing coronary artery bypass grafting (CABG).
dc.description.abstractA total of 60 patients undergoing CABG were randomized into 4 groups. St Thomas' Hospital cold crystalloid cardioplegia was used in groups A and B, and cold blood cardioplegia in groups C and D. Groups A and C received a placebo infusion of normal saline, whereas groups B and D were administered intravenous taurolidine. Arrhythmias induced by pro- and anti-inflammatory cytokines (interleukin [IL]-6 and IL-10), and I/R were assessed perioperatively.
dc.description.abstractAdministration of taurolidine in crystalloid cardioplegia patients resulted in a significant decrease in serum IL-6 and an increase in serum IL-10 at 24 hours postaortic unclamping compared to placebo (P < .0001). Although not statistically significant, this trend in serum IL-6 decrease was mirrored in the blood cardioplegia patients (P = .068). Taurolidine treatment also significantly decreased I/R-induced arrhythmias compared to placebo in the crystalloid cardioplegia patients (P < .003). There were fewer I/R-induced arrhythmias compared to placebo in the blood cardioplegia patients; the difference, however, was marginal and not statistically significant (P = .583).
dc.description.abstractThis study demonstrates that administration of taurolidine in CABG patients induces a potent anti-inflammatory response that is associated with a significant decrease in arrhythmias.
dc.language.isoenen
dc.publisherMosby Inc.en
dc.subject.meshAged
dc.subject.meshAntioxidants
dc.subject.meshCardiopulmonary Bypass
dc.subject.meshConstriction
dc.subject.meshCoronary Artery Bypass
dc.subject.meshEndotoxins
dc.subject.meshFemale
dc.subject.meshHeart Arrest, Induced
dc.subject.meshHumans
dc.subject.meshInterleukin-10
dc.subject.meshInterleukin-6
dc.subject.meshLength of Stay
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshPhagocytosis
dc.subject.meshPlacebos
dc.subject.meshReperfusion Injury
dc.subject.meshRespiratory Burst
dc.subject.meshTaurine
dc.titleThe antiendotoxin agent taurolidine potentially reduces ischemia/reperfusion injury through its metabolite taurine.en
dc.typeArticleen
dc.contributor.departmentDepartment of Cardiac Surgery, University College Cork, Cork University Hospital, Cork, Ireland.en
dc.identifier.journalSurgeryen
dc.description.provinceMunster
html.description.abstractCardiopulmonary bypass results in ischemia/reperfusion (I/R)-induced endotoxemia. We conducted a prospective randomized trial to investigate the effect of taurolidine, an antiendotoxin agent with antioxidant and membrane-stabilizing properties, on patients undergoing coronary artery bypass grafting (CABG).
html.description.abstractA total of 60 patients undergoing CABG were randomized into 4 groups. St Thomas' Hospital cold crystalloid cardioplegia was used in groups A and B, and cold blood cardioplegia in groups C and D. Groups A and C received a placebo infusion of normal saline, whereas groups B and D were administered intravenous taurolidine. Arrhythmias induced by pro- and anti-inflammatory cytokines (interleukin [IL]-6 and IL-10), and I/R were assessed perioperatively.
html.description.abstractAdministration of taurolidine in crystalloid cardioplegia patients resulted in a significant decrease in serum IL-6 and an increase in serum IL-10 at 24 hours postaortic unclamping compared to placebo (P < .0001). Although not statistically significant, this trend in serum IL-6 decrease was mirrored in the blood cardioplegia patients (P = .068). Taurolidine treatment also significantly decreased I/R-induced arrhythmias compared to placebo in the crystalloid cardioplegia patients (P < .003). There were fewer I/R-induced arrhythmias compared to placebo in the blood cardioplegia patients; the difference, however, was marginal and not statistically significant (P = .583).
html.description.abstractThis study demonstrates that administration of taurolidine in CABG patients induces a potent anti-inflammatory response that is associated with a significant decrease in arrhythmias.


Files in this item

Thumbnail
Name:
Publisher version

This item appears in the following Collection(s)

Show simple item record